GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: VG3927
Compound class:
Synthetic organic
Comment: VG-3927 (Vigil Neuroscience) is an orally available TREM2 agonist [2]. It is proposed to increase the neuroprotective functions of microglia, as a mechanism to combat Alzheimer's disease-driven brain pathologies.
|
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| VG-3927 is proposed as an Alzheimer's disease therapeutic. A phase 1 study has been completed. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT06343636 | A Phase 1 Study of VG-3927 in Healthy Adults and Patients With Alzheimer's Disease | Phase 1 Interventional | Vigil Neuroscience, Inc. | ||